Suppr超能文献

预测急性心力衰竭症状性患者早期速尿反应不良和早期托伐普坦疗效的因素。

Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.

机构信息

Department of Cardiology, Tokyo General Hospital, 3-15-2 Egota, Nakano-ku, Tokyo, 165-8906, Japan.

出版信息

Am J Cardiovasc Drugs. 2023 Mar;23(2):185-196. doi: 10.1007/s40256-023-00571-y. Epub 2023 Feb 4.

Abstract

BACKGROUND

Diuretic response (DR) in patients with symptomatic acute decompensated heart failure (ADHF) has an impact on prognosis. This study aimed to identify predictive factors influencing acute 6 h poor DR and to assess DR after early administration of tolvaptan (TLV).

METHODS

This multicenter retrospective study included 1670 patients who were admitted for ADHF and received intravenous furosemide within 1 h of presentation in clinical scenario 1 or 2 defined based on initial systolic blood pressure ≥100 mmHg with severe symptoms (New York Heart Association class III or IV (n = 830). The score for the poor DR factors in the very acute phase was calculated in patients treated with furosemide-only diuretics (n = 439). The DR to TLV administration was also assessed in patients who received an additional dose of TLV within 6 h (n = 391).

RESULTS

The time since discharge from the hospital for a previous heart failure < 3 months (odds ratio [OR] 2.78, 95% confidence interval [CI] 1.34-5.83; p = 0.006), loop diuretics at admission (OR 3.05, 95% CI 1.74-5.36; p < 0.0001), and estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m (OR 2.99, 95% CI 1.58-5.74; p = 0.0007) were independent determinants of poor DR. The frequency of poor DR according to the risk stratification group was low risk (no risk factor), 18.9%; middle risk (one risk factor), 33.1%; and high risk (two to three risk factors), 58.0% (p < 0.0001). All risk groups demonstrated a significantly lower incidence of poor DR with early TLV administration: 10.7% in the early TLV group versus 18.9% in the loop diuretics group (p = 0.09) of the low-risk group; 18.4% versus 33.1% (p = 0.01) in the middle-risk group, and 20.2% versus 58.0% (p < 0.0001) in the high-risk group.

CONCLUSION

Early administration of TLV in patients with predicted poor DR contributed to a significant diuretic effect and suppression of worsening renal function.

摘要

背景

有症状的急性失代偿性心力衰竭(ADHF)患者的利尿剂反应(DR)对预后有影响。本研究旨在确定影响急性 6 小时不良 DR 的预测因素,并评估早期给予托伐普坦(TLV)后的 DR。

方法

这是一项多中心回顾性研究,纳入了 1670 名因 ADHF 入院的患者,他们在临床情况 1 或 2 中于就诊后 1 小时内接受了静脉注射呋塞米,临床情况 1 或 2 基于初始收缩压≥100mmHg 且症状严重(纽约心脏协会心功能分级 III 或 IV 级(n=830)。在接受呋塞米单药利尿剂治疗的患者(n=439)中计算了非常急性阶段不良 DR 因素的评分。还评估了在 6 小时内接受额外 TLV 剂量的患者(n=391)的 TLV 给药后的 DR。

结果

出院后 3 个月内因心力衰竭再次入院的时间<3 个月(优势比 [OR] 2.78,95%置信区间 [CI] 1.34-5.83;p=0.006)、入院时使用袢利尿剂(OR 3.05,95% CI 1.74-5.36;p<0.0001)和估算肾小球滤过率(eGFR)<45mL/min/1.73m(OR 2.99,95% CI 1.58-5.74;p=0.0007)是不良 DR 的独立决定因素。根据风险分层组的不良 DR 发生率低风险(无风险因素)为 18.9%;中风险(一个风险因素)为 33.1%;高风险(两个至三个风险因素)为 58.0%(p<0.0001)。所有风险组均显示早期 TLV 给药可显著降低不良 DR 的发生率:低风险组中早期 TLV 组为 10.7%,而袢利尿剂组为 18.9%(p=0.09);中风险组为 18.4%比 33.1%(p=0.01),高风险组为 20.2%比 58.0%(p<0.0001)。

结论

对预测不良 DR 的患者早期给予 TLV 有助于产生显著的利尿作用并抑制肾功能恶化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验